CollPlant Biotechnologies CLGN
NASDAQ CLGN
$3.88 +0.32 (+8.99%)
As of: Oct 20, 2026 · 3:59 PM EDT

CollPlant Biotechnologies (CLGN) Convertible Debt (2019)

Updated

CollPlant Biotechnologies' Convertible Debt was $5.44 million in the quarter ended Sep 30, 2019.

Analysis

CollPlant Biotechnologies (CLGN) Convertible Debt (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 CollPlant Biotechnologies 4.68 Mn -17.68 Mn -456,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 5.44 Mn
API Access

CollPlant Biotechnologies Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=CLGN&period=max&api_key=YOUR_API_KEY